JP2011525477A5 - - Google Patents

Download PDF

Info

Publication number
JP2011525477A5
JP2011525477A5 JP2010549861A JP2010549861A JP2011525477A5 JP 2011525477 A5 JP2011525477 A5 JP 2011525477A5 JP 2010549861 A JP2010549861 A JP 2010549861A JP 2010549861 A JP2010549861 A JP 2010549861A JP 2011525477 A5 JP2011525477 A5 JP 2011525477A5
Authority
JP
Japan
Prior art keywords
vaccine composition
particles
aspect ratio
antigen
immunostimulatory agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010549861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525477A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/036068 external-priority patent/WO2009111588A1/en
Publication of JP2011525477A publication Critical patent/JP2011525477A/ja
Publication of JP2011525477A5 publication Critical patent/JP2011525477A5/ja
Pending legal-status Critical Current

Links

JP2010549861A 2008-03-04 2009-03-04 免疫調節剤粒子および処置方法 Pending JP2011525477A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6822708P 2008-03-04 2008-03-04
US61/068,227 2008-03-04
PCT/US2009/036068 WO2009111588A1 (en) 2008-03-04 2009-03-04 Immunomodulator particles and methods of treating

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014238952A Division JP2015078204A (ja) 2008-03-04 2014-11-26 免疫調節剤粒子および処置方法

Publications (2)

Publication Number Publication Date
JP2011525477A JP2011525477A (ja) 2011-09-22
JP2011525477A5 true JP2011525477A5 (enExample) 2012-04-26

Family

ID=41056361

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010549861A Pending JP2011525477A (ja) 2008-03-04 2009-03-04 免疫調節剤粒子および処置方法
JP2014238952A Pending JP2015078204A (ja) 2008-03-04 2014-11-26 免疫調節剤粒子および処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014238952A Pending JP2015078204A (ja) 2008-03-04 2014-11-26 免疫調節剤粒子および処置方法

Country Status (5)

Country Link
US (2) US20110151015A1 (enExample)
EP (1) EP2262480B1 (enExample)
JP (2) JP2011525477A (enExample)
CN (1) CN102014874A (enExample)
WO (1) WO2009111588A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055459A1 (en) * 2006-08-30 2010-03-04 Liquidia Technologies, Inc. Nanoparticles Having Functional Additives for Self and Directed Assembly and Methods of Fabricating Same
US20100190654A1 (en) * 2006-12-05 2010-07-29 Liquidia Technologies , Inc. Nanoarrays and methods and materials for fabricating same
AU2008222678B2 (en) 2007-03-07 2013-01-17 The General Hospital Corporation Compositions and methods for the prevention and treatment of autoimmune conditions
WO2010138192A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
EP2538969A4 (en) * 2010-02-22 2013-11-27 Liquidia Technologies Inc VACCINES FROM POLYSACCHARIDE PARTICLES
CN102905728B (zh) 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
US20130203675A1 (en) 2010-09-16 2013-08-08 Joseph M. DeSimone Asymmetric biofunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
US20150037428A1 (en) 2011-11-29 2015-02-05 The University Of North Carolina At Chapel Hill Geometrically engineered particles and methods for modulating macrophage or immune responses
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014165728A1 (en) * 2013-04-05 2014-10-09 The University Of North Carolina At Chapel Hill Particles having peg-ylated surfaces modified for lymphatic trafficking
JP2017500285A (ja) 2013-11-04 2017-01-05 ユーティーアイ リミテッド パートナーシップ 持続的免疫療法のための方法および組成物
SG10201913957PA (en) 2015-05-06 2020-03-30 Uti Lp Nanoparticle compositions for sustained therapy
US20190298854A1 (en) 2016-03-07 2019-10-03 Glaxosmithkline Biologicals, Sa Drug delivery particles
US10898494B2 (en) 2016-05-05 2021-01-26 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
JP7436372B2 (ja) 2017-11-29 2024-02-21 ユーティアイ・リミテッド・パートナーシップ 自己免疫性疾患を治療する方法
US20230241237A1 (en) * 2020-04-16 2023-08-03 Emory University Immune Cell Redirecting Compositions and Therapeutic Uses Thereof
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
GB9227068D0 (en) 1992-12-29 1993-02-24 British Bio Technology Novel proteinaceous particles
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5686113A (en) * 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
ATE215385T1 (de) * 1997-12-16 2002-04-15 Chiron Corp Verwendung von mikropartikeln mit submikron öl/wasser emulsionen
US6086881A (en) 1998-05-15 2000-07-11 Children's Medical Center Corp. Spatially aligned conjugated composition having a thioether bond linkage
CA2351593C (en) * 1998-11-11 2012-02-21 The Board Of Regents Of The University Of Oklahoma Polymer grafting by polysaccharide synthases
US6326021B1 (en) 1999-06-18 2001-12-04 The Ohio State University Research Foundation Biocompatible polymeric delivery systems having functional groups attached to the surface thereof
JP4658423B2 (ja) 1999-08-03 2011-03-23 ザ オハイオ ステイト ユニバーシティ Ｈｅｒ−２タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド
US20020061312A1 (en) 2000-07-31 2002-05-23 Ruslan Medzhitov Innate immune system-directed vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
AU2002305539A1 (en) 2001-05-09 2002-11-18 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
AU2003235685A1 (en) 2002-01-09 2003-07-30 Ruslan M. Medzhitov Rip2: a method of signaling in the innate and adaptive immune systems
US20030157539A1 (en) 2002-01-09 2003-08-21 Yale University IRAK-M is a negative regulator of toll-like receptor signaling
CA2481980A1 (en) * 2002-04-05 2003-10-23 Progenics Pharmaceuticals, Inc. Particle-bound human immunodeficiency virus envelope glycoproteins and related compositions and methods
AU2003225054A1 (en) 2002-04-19 2003-11-03 Yale University Toll-like receptor 11 and toll-like receptor 12
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US7393493B2 (en) * 2003-02-27 2008-07-01 A Enterprises, Inc. Crosslinkable polymeric materials and their applications
US20050163764A1 (en) 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
US20050118199A1 (en) * 2003-10-07 2005-06-02 Esser Mark T. Process for covalently conjugating polysaccharides to microspheres or biomolecules
EP1687024B1 (en) * 2003-11-05 2011-10-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
US8263129B2 (en) * 2003-12-19 2012-09-11 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro-and nano-structures using soft or imprint lithography
US9040090B2 (en) * 2003-12-19 2015-05-26 The University Of North Carolina At Chapel Hill Isolated and fixed micro and nano structures and methods thereof
CA2556169C (en) * 2004-01-29 2011-11-22 Andrew Lees Use of amino-oxy functional groups in the preparation of vaccines
CA2595783A1 (en) * 2005-02-01 2006-08-10 Medivas, Llc Vaccine delivery compositions and methods of use
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2007016039A (es) 2005-06-17 2008-10-27 Univ North Carolina Metodos, sistemas y materiales de fabricacion de nanoparticulas.
EP1951202A4 (en) 2005-11-07 2013-03-06 Univ North Carolina ISOLATED AND SOLID MICRO AND NANO STRUCTURES AND METHOD THEREFOR
WO2007081876A2 (en) * 2006-01-04 2007-07-19 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
WO2008063204A2 (en) 2006-01-27 2008-05-29 The University Of North Carolina At Chapel Hill Taggants and methods and systems for fabricating
CN101405028B (zh) * 2006-03-17 2015-08-19 美国政府健康及人类服务部 制备复合的多价免疫原性结合物的方法
US20080181958A1 (en) * 2006-06-19 2008-07-31 Rothrock Ginger D Nanoparticle fabrication methods, systems, and materials
US20100055459A1 (en) * 2006-08-30 2010-03-04 Liquidia Technologies, Inc. Nanoparticles Having Functional Additives for Self and Directed Assembly and Methods of Fabricating Same
ES2517869T3 (es) * 2006-09-12 2014-11-04 Alphavax, Inc. Partículas de replicones de alfavirus emparejadas con antígenos proteicos como adyuvantes inmunológicos
WO2008045486A2 (en) 2006-10-09 2008-04-17 The University Of North Carolina At Chapel Hill Nanoparticle compositions for controlled delivery of nucleic acids
EP2146689B1 (en) * 2007-04-16 2020-08-12 Corium, Inc. Solvent-cast microneedle arrays containing active

Similar Documents

Publication Publication Date Title
Hanif et al. Halloysite nanotubes as a new drug-delivery system: a review
Vinay et al. Recent advances in application of nanoparticles in fish vaccine delivery
Meyer et al. Biomimetic particles as therapeutics
Griffiths et al. Nanobead-based interventions for the treatment and prevention of tuberculosis
UY37326A (es) Dispersiones sólidas extruidas por fusión que contienen un agente inductor de apoptosis
Wang et al. Amphiphilic polymer-mediated formation of laponite-based nanohybrids with robust stability and pH sensitivity for anticancer drug delivery
JP2013530158A5 (enExample)
He et al. A dual macrophage targeting nanovector for delivery of oligodeoxynucleotides to overcome cancer-associated immunosuppression
AR093449A1 (es) Polvo farmaceutico compuesto de nucleo-recubrimiento y procedimientos para producirlo
JP2011178784A5 (enExample)
JP2015500342A5 (enExample)
JP2011037876A5 (enExample)
JP2014530219A5 (enExample)
JP2009512663A5 (enExample)
Ferrari et al. Halloysite nanotubes-polymeric nanocomposites: characteristics, modifications and controlled drug delivery approaches
JP2010047579A5 (enExample)
Leporatti Halloysite clay nanotubes as nano‐bazookas for drug delivery
JP2016513724A5 (enExample)
RU2014128590A (ru) Применение полимерных эксципиентов для лиофилизации или заморозки частиц
JP2008505857A5 (enExample)
JP2014526519A5 (enExample)
Sato et al. Intrapulmonary delivery of CpG microparticles eliminates lung tumors
Beletskii et al. Engineered PRINT® nanoparticles for controlled delivery of antigens and immunostimulants
Qin et al. Combatting Helicobacter pylori with oral nanomedicines
Zhang et al. Mucus as a barrier for biopharmaceuticals and drug delivery systems